Key result
Only ~33% of psychiatric outpatients taking second-generation antipsychotics receive a complete cardiovascular risk assessment.
Population
200 psychiatric outpatients treated with second-generation antipsychotics, recruited from two community…
Design
Cross-sectional
Authors
Loading...
Highlights gaps in cardiometabolic monitoring for SGA-treated outpatients; leaves open whether targeted protocols improve documentation or outcomes.
Observational (n=200)
Yes
Cardiovascular risk monitoring is poorly executed in psychiatric outpatients on second-generation antipsychotics, highlighting a critical need for systematic physical health assessment in this vulnerable population.
Severi et al. (2017) conducted an observational in Psychiatric illness (n=200). Second-generation antipsychotics was evaluated on Availability of a complete cardiovascular risk assessment. A complete cardiovascular risk assessment was available in only 33.3% (60 of 200) of psychiatric outpatients taking second-generation antipsychotics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: